Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
2 ]+ A4 K3 h" S s3 f, L6 U K' P9 Z, i! e8 P2 i
* t$ H% Q0 [8 D. O# C# S4 p$ GSub-category:
- i' \- B% }# E" K+ HMolecular Targets 9 p- ~' b8 i9 l% A- w
1 K+ e& m. \6 `( X* v0 r1 f
) X- t0 E/ F8 R! a
Category:$ V" H/ Z+ [1 m. ?
Tumor Biology + l* ~! }( b# Z' ]( T5 K
7 A$ i3 D) o+ f9 W+ f: ]8 H! ^7 g
8 l4 k* [& f! z7 M1 FMeeting:
% j: r, A" w `2011 ASCO Annual Meeting ! r3 P6 {% z# k$ H' f
! Y, ^" U5 b# p8 _9 d* D( {4 Z7 ^( o0 H& a( y% e# e& g
Session Type and Session Title:
% A+ f* Q' T. P- CPoster Discussion Session, Tumor Biology 7 H1 ^% Z& d7 H! k8 j. O
, u- N9 S4 V# S" H# I5 n; R1 R
/ E: V1 S; b" h1 wAbstract No:
8 D0 Y# o5 I+ V \8 R2 ^; Q2 m7 r% K10517 6 c1 D: K, h! Z
) |( a" `% `( R6 S- h
: y+ P7 _) C4 zCitation:
% Q" e+ \6 I' }( P: h$ [J Clin Oncol 29: 2011 (suppl; abstr 10517) # V- X2 N# J0 a3 g
3 m- U; ?' d" \" @" ?6 S) ~4 p
/ I* C/ D/ Y+ tAuthor(s):
, [) _# g/ x& UJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China ; C# ?3 X- m" j j% e7 i' {, r
8 G0 i* H1 z+ j% g
W5 Y6 c* z! r4 i
4 i. K9 ^+ \0 f m' cAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.0 {" o1 T1 X4 |7 G/ F' O* k. j, C
& l4 W- ]% k- @, E9 e1 xAbstract Disclosures- f5 t- N+ A1 V6 z! C, z
. Z/ U6 Z3 k4 t7 p' W" ?
Abstract:$ w/ t+ ?/ G3 Y
" h8 C8 D- g; p7 _
5 S& L9 j5 l/ ~+ iBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.) w( k9 |5 s! ]
% Y% E" S% O, A* X
' ~* b* T, P3 k3 c2 ~6 S
|
显身卡
